[
  {
    "ts": "2025-01-16T13:00:00+00:00",
    "headline": "Charles River and Akron Bio Announce Collaboration to Enhance Operations with Integration of CGMP Materials into Cell Therapy Platform",
    "summary": "WILMINGTON, Mass., January 16, 2025--Charles River Laboratories International, Inc. (NYSE: CRL) and Akron Bio (\"Akron\"), a leading supplier of critical materials and services for advanced therapies, today announced the integration of Akron’s Closed System Solutions (CSS)™ line of liquid cytokines produced under current good manufacturing practices (CGMP) onto Charles River’s Cell Therapy Flex Platform for Process Development. The integration of Akron’s line of liquid cytokines further enables cl",
    "url": "https://finance.yahoo.com/news/charles-river-akron-bio-announce-130000785.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "71360cf2-5ec0-35b6-84b1-dbdaffc8d6bd",
      "content": {
        "id": "71360cf2-5ec0-35b6-84b1-dbdaffc8d6bd",
        "contentType": "STORY",
        "title": "Charles River and Akron Bio Announce Collaboration to Enhance Operations with Integration of CGMP Materials into Cell Therapy Platform",
        "description": "",
        "summary": "WILMINGTON, Mass., January 16, 2025--Charles River Laboratories International, Inc. (NYSE: CRL) and Akron Bio (\"Akron\"), a leading supplier of critical materials and services for advanced therapies, today announced the integration of Akron’s Closed System Solutions (CSS)™ line of liquid cytokines produced under current good manufacturing practices (CGMP) onto Charles River’s Cell Therapy Flex Platform for Process Development. The integration of Akron’s line of liquid cytokines further enables cl",
        "pubDate": "2025-01-16T13:00:00Z",
        "displayTime": "2025-01-16T13:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/ec0fde79fa4b333e41c914fd5d8c8c28",
          "originalWidth": 1245,
          "originalHeight": 326,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/aWtK3UJg3t.K1LlRVcZOHA--~B/aD0zMjY7dz0xMjQ1O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/ec0fde79fa4b333e41c914fd5d8c8c28.cf.webp",
              "width": 1245,
              "height": 326,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.AugcMOSwVQFCsbjSJrveA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/ec0fde79fa4b333e41c914fd5d8c8c28.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/charles-river-akron-bio-announce-130000785.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/charles-river-akron-bio-announce-130000785.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CRL"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]